Related Experiment Video
Updated: May 4, 2026
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Towards nanomedicines for neuroAIDS
Vidya Sagar1, Sudheesh Pilakka-Kanthikeel, Ravi Pottathil
1Center for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA; Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Nanotechnology offers promising solutions for delivering antiretroviral drugs across the blood-brain barrier to treat neuroAIDS. Further research is needed to optimize nanocarrier delivery, specificity, and bioavailability for effective treatment of HIV in the central nervous system.
Area of Science:
- Neuroscience
- Nanomedicine
- Pharmacology
Background:
- Highly active antiretroviral therapy (HAART) has reduced AIDS morbidity/mortality, but controlling HIV in the central nervous system (CNS) remains challenging.
- Antiretroviral drugs often fail to cross the blood-brain barrier (BBB), making the CNS a viral reservoir and leading to neurodegeneration in HIV infection.
- Effective drug delivery to the CNS is crucial for managing neuroAIDS and preventing further neuronal damage.
Purpose of the Study:
- To explore the potential of nanotechnology-based drug delivery systems for enhancing antiretroviral drug penetration into the CNS.
- To review various nanocarriers investigated for delivering antiretroviral drugs and neuroprotective agents across the BBB.
- To identify challenges and future research directions for optimizing nanodrug delivery for neuroAIDS treatment.
Main Methods:
- Review of current literature on nanotechnology applications in antiretroviral drug delivery for CNS penetration.
- Exploration of various nanocarrier systems, including liposomes, dendrimers, nanoparticles, micelles, and solid lipid nanoparticles.
- Discussion of emerging strategies like magnetic nanoparticles and monocyte/macrophage-based carriers for improved BBB crossing.
Main Results:
- Nanotechnology presents a promising avenue for developing novel drug delivery systems to achieve therapeutic levels of antiretroviral drugs in the CNS.
- Various nanocarriers have been explored, demonstrating potential for crossing the BBB and delivering drugs.
- Emerging carriers like magnetic nanoparticles and monocytes show enhanced delivery capabilities.
Conclusions:
- Nanotechnology holds significant potential for targeted and effective delivery of antiretroviral drugs to the CNS, addressing a critical challenge in neuroAIDS treatment.
- Further research is essential to overcome limitations in target specificity, controlled release, and bioavailability of nanoformulated drugs for neuroAIDS.
- Optimizing nanocarrier systems is key to achieving desired drug concentrations in the brain and combating HIV progression in the CNS.
